Optimization of Sphingosine-1-phosphate-1 Receptor Agonists: Effects of Acidic, Basic, and Zwitterionic Chemotypes on Pharmacokinetic and Pharmacodynamic Profiles-Reference-Cited by-同舟云学术

Optimization of Sphingosine-1-phosphate-1 Receptor Agonists: Effects of Acidic, Basic, and Zwitterionic Chemotypes on Pharmacokinetic and Pharmacodynamic Profiles

Published:2014-12-15 Issue:24 Volume:57 Page:10424-10442
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Skidmore John¹,Heer Jag¹,Johnson Christopher N.¹,Norton David¹,Redshaw Sally¹,Sweeting Jennifer¹,Hurst David¹,Cridland Andrew¹,Vesey David¹,Wall Ian¹,Ahmed Mahmood²,Rivers Dean²,Myatt James¹,Giblin Gerard¹,Philpott Karen¹,Kumar Umesh¹,Stevens Alexander¹,Bit Rino A.³,Haynes Andrea³,Taylor Simon³,Watson Robert³,Witherington Jason³,Demont Emmanuel³,Heightman Tom D.¹

Affiliation:

1. Neurology Center of Excellence for Drug Discovery, GlaxoSmithKline, New Frontiers Science Park, Harlow CM19 5AW, U.K.

2. Neural Pathways DPU, GlaxoSmithKline, 11 Biopolis Way, Singapore 138667

3. Immuno Inflammation Center of Excellence for Drug Discovery, GlaxoSmithKline, Gunnels Wood Road, Stevenage, SG1 2NY, U.K.

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm5010336

Reference41 articles.

1. Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis